Deutsche Bank's research report on Aegerion Pharmaceuticals, providing an update after discussions with management. The report highlights increased SG&A expenses for 2014, plans for sales force expansion, and customer care investments. It also discusses the company's profitability guidance and EU reimbursement expectations. The report reiterates a 'Buy' rating with a price target of $115.
documents/vol00010-efta01461182-pdf.pdf
{"title":"Deutsche Bank Markets Research - Aegerion Alert","key_people":["Robyn Kamauskas","Alethia Young"],"document_date":"2013-11-18","document_type":"tabular","key_locations":["United States","European Union"],"document_subtype":"Company Research Report","key_organizations":["Deutsche Bank","Aegerion Pharmaceuticals"]}